Why Vicor (VICR) Is Up 6.5% After Bullish AI Power Delivery Analyst Coverage And What’s Next

• Vicor Corporation recently received positive analyst coverage, with research firms highlighting its positioning in power delivery solutions for next‑generation AI platforms, underpinned by new product rollouts, a vertically integrated fabrication facility, and an expanding intellectual property licensing business.
• Analysts also pointed to Vicor’s preparation for a major ramp‑up of its second‑generation vertical power delivery solutions for a lead customer in early 2026, suggesting its technology is becoming increasingly embedded in high‑performance data center and AI infrastructure.
• Next, we’ll examine how Vicor’s planned ramp‑up of second‑generation AI power delivery solutions could reshape its existing investment narrative.

Trump has pledged to “unleash” American oil and gas and these 22 US stocks have developments that are poised to benefit.

Vicor Investment Narrative Recap

To own Vicor, you need to believe its vertical power delivery technology and IP portfolio can stay central to next generation AI and data center power needs, while the company manages customer concentration and demand volatility. The latest bullish analyst coverage reinforces the importance of the 2026 ramp for second generation vertical power delivery as the key near term catalyst, but it does not remove the risk that order instability and backlog softness could still unsettle results.

Among recent developments, Vicor’s strong Q2 and Q3 2025 results, with Q3 revenue of US$110.42 million and net income of US$28.29 million, stand out as especially relevant. They show how meaningful product and licensing contributions can be when demand aligns, which is exactly what investors are watching for as the second generation AI power delivery ramp approaches and the company works through earlier backlog and book to bill concerns.

Yet while the AI opportunity is attracting attention, investors should also be aware that Vicor’s reliance on large, timing sensitive IP and licensing outcomes…

Read the full narrative on Vicor (it’s free!)

Vicor’s narrative projects $523.8 million revenue and $45.4 million earnings by 2028. This requires 11.4% yearly revenue growth and a $20.1 million earnings decrease from $65.5 million today.

Uncover how Vicor’s forecasts yield a $93.75 fair value, a 34% downside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community members currently see Vicor’s fair value between US$51.52 and US$115, underlining how far apart expectations can be. Set this against the upcoming 2026 production ramp and existing order instability, and it becomes clear why you may want to weigh multiple viewpoints before forming a view on Vicor’s potential performance.

Explore 3 other fair value estimates on Vicor – why the stock might be worth as much as $115.00!

Build Your Own Vicor Narrative

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

• A great starting point for your Vicor research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Vicor research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Vicor’s overall financial health at a glance.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer’s.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com